2022 AIM-HI Women’s Venture Competition Announced 6 Semi-Finalists!
The AIM-HI Accelerator Fund (AIM-HI) just announced 6 Semi-Finalists for the 2022 AIM-HI Women’s Venture Competition! These innovative oncology start-ups have been selected from an exceptional pool of applications submitted by women scientist-entrepreneurs worldwide. The AIM-HI Women’s Venture Competition, now…
Leading Game-changing Discoveries | Sujuan Ba, Ph.D.
We're excited that Dr. Sujuan Ba, AIM-HI CEO & Co-Founder, is featured as one of the "20 Most Inspiring Women Leaders 2022" by THE WOMEN LEADERS Magazine. Read about her illustrious career leading three successful non-profits in the field of cancer…
AIM-HI CEO & Co-Founder Featured as ‘Scientist Trailblazing the Transformation’
Recently, Sujuan Ba, Ph.D., CEO & Co-Founder of the AIM-HI Accelerator Fund, was featured in the series Profiles in Success as a Scientist Trailblazing the Transformation. In the interview, Dr. Ba highlights her path from determined teen to research and eventually nonprofit leadership.…
Investing in the Healthcare Sector: How to Help Humanity and Make Money at the Same Time
by Cristina Campabadal In the last year and a half of the pandemic, we have become aware of the great importance of healthcare. And even more, after seeing hospitals all over the world saturated, even having to temporarily build others,…
2021 Highlights: Thank You for Supporting AIM-HI to Accelerate a Cure!
The year 2021 saw an unprecedented triumph of science as the world witnessed the fastest vaccine development in history. That is the result of decades of investments in basic cancer research. The AIM-HI Accelerator Fund has made decisive progress in…
Applications Open for the 2022 AIM-HI Women’s Venture Competition!
We have great news to share! The 2022 AIM-HI Women’s Venture Competition is Now Open for Applications! This unique funding program, now in its third year, provides investment, coaching, and networking opportunities to women-led oncology startups. Companies with a woman…
Entrepreneurship: Fundamentals for Academics Starting a Biotech Company
by Ronald DePinho, M.D. We just passed the 40th anniversary of the biotech industry, a birth made possible by the confluence of a seminal patent in recombinant DNA technology, the successful IPO of the first biotech company Genentech, validation of…
Celebrating Progress in Cancer Research and Entrepreneurship!
The AIM-HI Accelerator Fund is fiercely dedicated to accelerating the commercialization of innovative lab breakthroughs into life-saving new therapies and technologies. These words evoke a pathway. A pathway of progress that connects cancer research lab breakthroughs to game-changing novel technologies.…
2021 Women’s Venture Competition Announced Semi-Finalists!
The AIM-HI Accelerator Fund just announced 10 semi-finalists for the 2021 Women’s Venture Competition! These oncology companies have been selected from among an exceptional pool of applications submitted globally by women scientist-entrepreneurs. Decision making was led by a selection committee…
Tvardi Therapeutics Raises $74 Million in Series B Financing to Advance Clinical Programs
Tvardi Therapeutics, Inc. (“Tvardi”) a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, has closed a $74 million Series B financing. The financing was led by new investors Slate Path Capital, Palkon Capital, ArrowMark Partners, and…
Making Cancer Patient Clinical Trial Recruitment & Engagement Easier
Are you struggling to increase clinical trial awareness, recruitment, and participant retention for your oncology drug trials? Building up an efficient pre-screening process becomes an urgent task for companies to connect with potential participants; keep them engaged through the trial…
Privo Technologies, Inc. to Present Phase II Data for PRV111 in Head and Neck Squamous Cell Carcinoma at the Upcoming 2021 ASCO Annual Meeting
Privo Technologies, Inc. ("Privo"), a biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be "Tough on cancer, Easy on patients", announced today a poster presentation on the safety and efficacy of PRV111 in patients with early-stage Head and Neck Squamous Cell…